Immunodeficiency News and Research

RSS

Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to fight infectious disease is compromised or entirely absent.

FDA updates dosing recommendation for Valcyte medication

The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant.

16 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Research Roundup: Shifting ER visits to urgent care centers; Evaluating doctors; Medicare Advantage quality ratings

Health Affairs: Many Emergency Department Visits Could Be Managed At Urgent Care Centers And Retail Clinics - Researchers analyzed samples of patient records and found "13.7 percent of all emergency department visits could take place at a retail clinic" - 7.9 percent when hours are restricted - and "an additional 13.4 percent of emergency department visits could take place at a urgent care center—8.9 percent when hours are restricted.

10 Sep 2010

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that clinical trial data demonstrating that the Company's lead HIV drug, KP-1461, resulted in increased HIV mutations consistent with the Viral Decay Acceleration mechanism will be featured in a late-breaker oral presentation by James Mullins, Ph.D., Professor of Microbiology and Medicine at the University of Washington, at the upcoming 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston, MA.

10 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) finalize its Proposed Rule regarding reimbursement to better ensure patient access to vital medicines in the hospital outpatient setting.

8 Sep 2010

NIH announces award to improve human microbiome research

The National Institutes of Health today announced it has awarded approximately $42 million to expand the scope of eight demonstration projects designed to link changes in the human microbiome to health and disease.

8 Sep 2010

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

8 Sep 2010

Teleflex partners with Access Scientific to distribute The PICC WAND vascular access device

Teleflex has partnered with Access Scientific Incorporated, San Diego, California to become the U.S. distributor of The PICC WAND™ Safety Introducer with ARROW® peelable sheath. This new, all- in-one vascular access device provides clinicians a faster, safer, simpler way to insert a peel away sheath for PICC or Midline catheter placements.

7 Sep 2010

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold.

7 Sep 2010

Human endogenous retroviruses may provide insight evidence to HIV diagnosis

Why is it so hard to isolate and purify human immunodeficiency virus (HIV).Why has no one been able to see, by electron microscopy, a single HIV particle in the blood of AIDS patients, even those who have a "high viral load" Why does HIV seem to mutate with startling rapidity. AIDS researchers have not been able to come up with answers to these questions.

4 Sep 2010

Researchers find role of Vpr protein in HIV infection

Dr. Éric A. Cohen, Director of the Human Retrovirology research unit at the Institut de recherches cliniques de Montréal (IRCM), and his team published yesterday, in the online open-access journal PLos Pathogens, the results of their most recent research on the role of the Vpr protein in HIV (human immunodeficiency virus) infection and AIDS (acquired autoimmune deficiency syndrome).

3 Sep 2010

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

New TB diagnostic test effective in first large-scale field trial

Research assessing the effectiveness of a new diagnostic test for the detection of tuberculosis (TB) is featured in the Sept. 1 edition of the New England Journal of Medicine.

3 Sep 2010

Scientist suggests guidelines to safeguard physical health in college

College can be some of the best years of a person's life. But it is also a critical time, a time when students need to be aware of their health and safety. For women, many on their own for the first time in their lives, developing the ability to safeguard their emotional and physical health is paramount.

30 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.

24 Aug 2010

Brain can act as a hiding place for HIV virus: Study

Studies of the spinal fluid of patients given anti-HIV drugs have resulted in new findings suggesting that the brain can act as a hiding place for the HIV virus. Around 10% of patients showed traces of the virus in their spinal fluid but not in their blood.

23 Aug 2010

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, from 18 months to 24 months. Hizentra, the first and only 20 percent subcutaneous immunoglobulin (SCIg) approved in the U.S. by the FDA, is also the first and only SCIg in the U.S. that may be stored at room temperature.

19 Aug 2010

Immunodeficiency News and Research

Further Reading

FDA updates dosing recommendation for Valcyte medication

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Research Roundup: Shifting ER visits to urgent care centers; Evaluating doctors; Medicare Advantage quality ratings

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

PPTA supports CMS' proposal for hospital outpatient reimbursement for plasma protein therapies

NIH announces award to improve human microbiome research

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Teleflex partners with Access Scientific to distribute The PICC WAND vascular access device

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Human endogenous retroviruses may provide insight evidence to HIV diagnosis

Researchers find role of Vpr protein in HIV infection

Californians recognized for contributing to plasma protein lifesaving therapies

New TB diagnostic test effective in first large-scale field trial

Scientist suggests guidelines to safeguard physical health in college

Aethlon Medical receives approval for Chronic HCV Infection treatment

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Brain can act as a hiding place for HIV virus: Study

FDA approves CSL Behring's sBLA to extend shelf life of Hizentra from 18 to 24 months

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News